About me
Kathryn A. Cunningham, Ph.D., has catalyzed translational research in neuropsychiatry disorders with a particular emphasis on substance use disorders (SUDs). She has established strengths in phenotyping in preclinical and human research, pioneered the study of biological signaling networks for serotonin receptors, patented novel chemical molecules for future SUD therapeutics, and conducted human laboratory and clinical trials. Dr. Cunningham has been continuously funded by NIH, foundations, and industry for 30 years, has developed new technologies and has made seminal observations and developed new technologies which are described in 170+ peer-reviewed publications, and contributed 40+ research-related chapters, reviews and/or commentaries. She has life-long commitment to diversity, equity and inclusion as a driver of excellence in science and education. She received the College on Problems of Drug Dependence Mentorship Award, based her mentees’ nomination, the 2020 UTMB Mentorship Award and the 2022 UTMB Academy of Research Mentors Lifetime Achievement Award. Her commitment to community engagement has spanned over 30 years, and she has been recognized with the Angel Among Us Award for Long-Standing Community Support of Women in Recovery, and the Cruisin’ to Recovery Community Award.
